Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.




This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

Study Group: Generic Pharmaceuticals Economic Experts (Germany)(?)

Council Members in this Study Group: 35

This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.

Request a survey with this Study Group







Leading Experts in this Study Group

What is a GLG Leader?
John Ansell, MBA, Director, John Ansell ConsultancyJohn Ansell, MBA
Director
John Ansell Consultancy

John Ansell, BSc, MA, has been a pharmaceutical industry consultant since 1990, based in Thame, near Oxford, UK. He was employed for 20 years in the industry by Organon, Schering AG, Fisons, Solvay and Glaxo. His experience there and subsequently as a consultant is chiefly in business development, licensing,...

Jan Hacker, Managing Partner, Oberender & PartnerJan Hacker
Managing Partner
Oberender & Partner

Jan Hacker is the Managing Partner and Co-founder of Oberender & Partner, a leading Healthcare Consulting Company in Germany. Mr. Hacker has expertise in strategic hospital management and the development of market entry strategies for foreign companies. He is also a member of the board of EconoMedic...

GLG NewsSMAnalyses by this Study Group's Experts(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
Chinese generics is nothing new | 05-21-2008
Analysis of: China Muscles In On The Generics Industry | www.pharmalot.com
Author: John Ansell, MBA, Director, John Ansell Consultancy

In 1976, sitting in my office in International Marketing at Fisons, Loughborough, UK, I used to watch the drums of bulk paracetamol arriving at the factory from China - easily recognizable from the Chinese script decorating them. I'm sure the UK wasn't the only country importing raw materials from China...

Abbott's Humira: a key step towards market leadership in psoriasis | 01-08-2008
Author: John Ansell, MBA, Director, John Ansell Consultancy

European approval for Humira in psoriasis is a key step towards leadership over the other monoclonal antibodies already approved - and because this is the most valuable category, leadership also of the total psoriasis market. In April 2007 Abbott submitted this indication for approval to...

Exubera - approvable is no longer reimbursable | 10-24-2007
Author: GLG Expert Contributor

Exubera is the first major product to fail primarily due to Pfizer's inability to convince payors of it's value for money There is now significant additional risk in achieving market access after regulatory approval. Pricing and reimbursement decisions will play an increasingly important role in the...

Lundbeck and anticancer applications | 10-09-2007
Author: John Ansell, MBA, Director, John Ansell Consultancy

This move conforms with Lundbeck's strategy to concentrate on CNS areas and to bring in other parties to develop non-CNS applications.

HIV vaccines - time to face the hard reality ? | 10-01-2007
Author: John Ansell, MBA, Director, John Ansell Consultancy

Persisting with developing a vaccine for HIV may be no more realistic than attempting to produce one for the common cold. There is a link - both are caused by adenoviruses. If Merck, after 20 years has not succeeded for HIV, shouldn't development resources on vaccines now be channeled to more productive...

View All GLG News by members of this Study Group

Most Common Company Types:

  • Consultancy, Healthcare-Focused
  • Consultancy, Pharma-Focused
  • Pharmacy or Drug Store, Independent/Local
  • Academic Institution*
  • Pharmaceuticals Manufacturer
  • Strategic Management
  • Academic Medical Center/Hospital or Clinic
  • Drug Distributor, General or Full-Spectrum
  • Individual/Small Consultancy
  • Law Firm (general practice/large)
  • Office Based Private Practice or Clinic
  • Professional or Industry Association*

Most Common Job Types:

  • Director
  • Owner
  • Principal
  • Consultant
  • President
  • Project Manager

GLG's 750+ Clients Include:

40 of the leading 50
global mutual funds
15 of the leading 20
global banks
8 of the leading 10
private equity firms
90%+ client subscription renewal rate

Analytics